{
    "2019-10-10": [
        [
            {
                "time": "2018-10-10",
                "original_text": "Why This Biotech Stock Was Bullish Enough To Relicense Its Own Drugs",
                "features": {
                    "keywords": [
                        "biotech",
                        "bullish",
                        "rellicense",
                        "drugs"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-10",
                "original_text": "J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector",
                "features": {
                    "keywords": [
                        "J&J",
                        "earnings",
                        "Q3",
                        "pharma"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-10",
                "original_text": "Top Ranked Income Stocks to Buy for October 10th",
                "features": {
                    "keywords": [
                        "income",
                        "stocks",
                        "buy",
                        "October"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "dividend",
                        "income"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-10",
                "original_text": "The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",
                "features": {
                    "keywords": [
                        "biotech",
                        "UCB",
                        "Ra Pharma",
                        "Reata",
                        "Nrf2",
                        "AbbVie",
                        "BioNTech",
                        "IPO"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}